Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy

INTRODUCTION: Tumor vaccine has been a research boom for cancer immunotherapy, while its therapeutic outcome is severely depressed by the vulnerable in vivo delivery efficiency. Moreover, tumor immune escape is also another intractable issue, which has badly whittled down the therapeutic efficiency....

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Mingxia, Zhao, Liping, Cui, Xiaoming, Wu, Xinghan, Zhang, Yuhan, Guan, Xiuwen, Ma, Jinlong, Zhang, Weifen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721234/
https://www.ncbi.nlm.nih.gov/pubmed/35003793
http://dx.doi.org/10.1016/j.jare.2021.08.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721234/
https://www.ncbi.nlm.nih.gov/pubmed/35003793
http://dx.doi.org/10.1016/j.jare.2021.08.011

Ejemplares similares